Groundbreaking findings from the landmark CLEAR (Clinical trial Comparing Lenvatinib with Ecerolimus or Pembrolizumab in ...

A groundbreaking study shows findings that show a treatment can shrink tumors and improve survival outcomes for patients with ...

Senior doctors responsible for monitoring cancer care in England and Wales are concerned failings in NHS services are ...

All nine patients treated with a personalized cancer vaccine following removal of their tumors remained cancer-free at a median data cut-off of 34.7 months.

Dr. Katy Beckermann discusses how a Fotivda and Opdivo combination for renal cell carcinoma compared with Fotivda alone based ...

Neoantigen-targeting PCVs are highly immunogenic in high-risk clear cell RCC and can target key driver mutations and induce antitumor immunity.

There could be new hope on for kidney cancer patients. Researchers announced early results of an anti-tumor vaccine for ...

The news comes on the heels of promising Phase I/Ib data, which point to the potential of casdatifan as a more effective ...

Avelumab maintenance with axitinib interruption was feasible in metastatic renal cell carcinoma responders, according to ...

Casdatifan’s progression-free survival benefits could help differentiate it from Merck’s Welireg in the kidney cancer arena, ...

Proactive onco-coaching did not improve quality of life but was linked to better overall survival in patients with metastatic ...

Thomas E. Hutson, D.O., Pharm.D., Ph.D., chief of the Hematology Oncology Division in the Department of Internal ...